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Abstract
 
Antigen presentation by major histocompatibility complex class II molecules is essential for an-
tibody production and T cell activation. For most class II alleles, peptide binding depends on
the catalytic action of human histocompatibility leukocyte antigens (HLA)-DM. HLA-DO is
selectively expressed in B cells and impedes the activity of DM, yet its physiological role re-
mains unclear. Cell surface iodination assays and mass spectrometry of major histocompatibility
complex class II–eluted peptides show that DO affects the antigenic peptide repertoire of class
II. DO generates both quantitative and qualitative differences, and inhibits presentation of
large-sized peptides. DO function was investigated under various pH conditions in in vitro
 
peptide exchange assays and in antigen presentation assays using DO
 
2
 
 and DO
 
1
 
 transfectant
cell lines as antigen-presenting cells, in which effective acidification of the endocytic pathway
 
was prevented with bafilomycin A
 
1
 
, an inhibitor of vacuolar ATPases. DO effectively inhibits
antigen presentation of peptides that are loaded onto class II in endosomal compartments that
are not very acidic. Thus, DO appears to be a unique, cell type–specific modulator mastering
the class II–mediated immune response induced by B cells. DO may serve to increase the
threshold for nonspecific B cell activation, restricting class II–peptide binding to late endosomal
compartments, thereby affecting the peptide repertoire.
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Introduction
 
The immune response against exogenous antigens requires
presentation of antigenic fragments by MHC class II mole-
cules at the cell surface of APCs (1). As these peptides are
predominantly generated in the endosomal and lysosomal
pathway, MHC class II molecules are directed into this
pathway after synthesis. For this, they associate in the endo-
plasmic reticulum to the invariant chain (Ii),
 
1
 
 containing
the targeting signal for endosomal sorting (2). During trans-
port to lysosomal-like compartments, where the majority
of antigen loading occurs (termed MHC class II peptide-
loading compartment [MIIC]), the Ii is proteolytically re-
moved, leaving only a small fragment (class II–associated
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invariant chain peptides [CLIP]) in the class II peptide
binding groove (3, 4).
Release of CLIP is needed to allow antigen binding to
class II (5). It requires the action of HLA-DM, another
MHC-like molecule (6, 7) that predominantly localizes to
the MIICs (8). In mutant cells or mice lacking functional
DM, CLIP remains associated to class II, which severely
hampers antigen presentation (9–12). In addition, DM cat-
alyzes dissociation of other nonstably bound peptides from
class II, thus acting as a peptide editor that favors presenta-
tion of stably bound peptides (13–18). During peptide
loading, some class II molecules escape the editing action of
DM, as demonstrated by the presence of a low, but detect-
able amount of class II/CLIP at the cell surface (5).
Recently, another MHC-encoded heterodimer, HLA-
DO (19, 20), was found in tight association with DM in B
cells (21). This association is a prerequisite for exit of DO
from the endoplasmic reticulum and subsequent targeting
into the endosomal pathway. Like DM, the predominant
localization of the DM–DO complex is in the MIICs. The
function of DO is still controversial. DO inhibits the cata-
lytic action of DM, impeding class II–CLIP dissociation
and reducing, but not abolishing, presentation of specific
antigenic peptides (22, 23). Moreover, B cells of H2-O–
deficient mice (H2-O is the murine equivalent of DO)
have a changed capacity to present particular antigens (24).
Since DO appears to be best expressed in resting B cells
(our unpublished results), these findings suggest that DO
may be involved in controlling B cell–driven immune re-
sponses. Still, the physiological function and purpose of
DO remain elusive.
We here report that DO forms a modulator of the anti-
genic peptide repertoire that is presented by MHC class II
molecules. DO both limits antigen presentation as a whole,
and simultaneously alters the actual composition of the set
of class II–associated peptides. Mechanistically, DO is dem-
onstrated to inhibit DM-mediated class II–peptide loading
best at the pH of the early endocytic compartments. As a
consequence, DO skews the peptide repertoire to those
peptides that are loaded onto class II in acidic compart-
ments, like the MIICs, while impeding peptide loading in
earlier, less acidic compartments of the endosomal/lysoso-
mal pathway.
 
Materials and Methods
 
Cell Lines, Transfectants, and Antibodies.
 
Stable transfectants of
the melanoma cell line Mel JuSo (HLA-A1, HLA-B8, HLA-
Cw7, HLA-DR3, and HLA-DQ2 by DNA typing) either trans-
fected with HLA-DO
 
a
 
 (19), HLA-DO
 
b
 
–green fluorescent pro-
tein (GFP), or vector only (20, 23), were grown in Iscove’s
medium with 10% FCS, 2,000 
 
m
 
g/ml G418, and/or 600 
 
m
 
g/ml
hygromycin (GIBCO BRL). Continuous and homogenous ex-
pression of the GFP-tagged proteins was ensured by regular selec-
tion of the GFP
 
1
 
 cells by FACS
 
®
 
. B lymphocytes, derived from
peripheral blood from healthy donors, were purified with anti-
CD19 Dynabeads
 
®
 
 and detached with the corresponding DE-
TACHaBEAD
 
®
 
, according to the manufacturer’s instructions
 
(Dynal). The HLA-DR–specific mAbs L243 (25) and 1B5 (26),
the CLIP-specific antibody CerCLIP.1 (27), the DR3–antigenic
peptide specific mAb 16.23 (28, 29), the DM
 
a
 
-specific mAb 5C1
(30), the rabbit anti-DO
 
b
 
 serum (23), and the Ii-specific poly-
clonal sera ICN2 and ICC5 (31) have been described (8). The
antiactin mAb Ab-1 was obtained from Oncogene Research
Products and the Texas red–conjugated secondary antibodies
from Molecular Probes.
 
DNA Constructs. 
 
The cDNAs encoding HLA-DO
 
a
 
 (19)
and HLA-DO
 
b
 
 (20) were respectively cloned into pcDNA3 (In-
vitrogen) and a variant of pCEP4 (Invitrogen) disabled for episo-
mal replication. The generation of a fusion construct between
GFP and the COOH terminus of DO
 
b 
 
(DO
 
b
 
GFP) has been de-
scribed (23). Other DNA manipulations were carried out using
standard procedures (32).
 
Biochemical and Western Blot Analyses. 
 
Cell surface labeling of
proteins was performed by lactoperoxidase-catalyzed iodination
with 1 mCi Na
 
125
 
I on cells grown to subconfluency in a 75-cm
 
2
 
tissue culture flask. Cells were washed four times with cold PBS,
lysed in Tris lysis buffer (pH 7.4) containing 0.5% NP-40 and 2
 
m
 
M PMSF (Sigma Chemical Co.), and used for immunoprecipi-
tations with normal rabbit serum, mAb 1B5, and the polyclonal
sera ICN2 and ICC5. Samples were loaded such that they were
related to equal amounts of recovered radioactive class II mole-
cules and separated by 12.5% SDS-PAGE. For pulse–chase analy-
sis, cells (grown to subconfluency in 6 Ø cm dishes) were pulsed
for 30 min with 0.1 mCi 
 
l
 
-[
 
35
 
S]methionine and 
 
l
 
-[
 
35
 
S]cysteine
(Amersham Pharmacia Biotech) in methionine- and cysteine-free
RPMI 1640 medium after deprivation of the cells of methionine
and cysteine for 30 min and chased upon addition of cold me-
thionine/cysteine to a final concentration of 1 
 
m
 
M. Cells were
either lysed in NP-40–containing lysis buffer immediately or after
chase periods for up to 8 h in complete medium at 37
 
8
 
C. Class II
molecules were recovered from equal amounts of TCA-precipi-
table radioactivity using the 1B5 antibody. Immunoprecipitates
were analyzed by 12.5% SDS-PAGE. To determine the relative
expression levels of DM and DO, equal amounts of total protein
were Western blotted using the anti-DM mAb 5C1 (30), the an-
tiactin mAb Ab-1 (Oncogene), or the anti-DO
 
b
 
 serum, and spe-
cific protein amounts were quantified using the FluorChem™
imaging system and analyzed with AlphaEase™ FluorChem™
software (Alpha Innotech Corp.). 
 
FACS
 
®
 
 Analysis.
 
10
 
6
 
 cells were stained with saturating
amounts of unlabeled primary antibody and PE-conjugated
F(ab
 
9
 
)
 
2
 
 rabbit anti–mouse IgG (heavy and light chains; Zymed)
and analyzed on a FACScan™ flow cytometer (Becton Dickin-
son).
 
MHC Class II Peptide Isolation, Reversed Phase HPLC, Mass
Spectrometry, and Peptide Sequencing. 
 
HLA-DR3–peptide com-
plexes were purified from 
 
.
 
10
 
10
 
 Mel JuSo cells transfected with
DO
 
ab
 
GFP (FACS
 
®
 
-sorted for homogenous DO
 
ab
 
GFP expres-
sion) or with vector only. Peptides were eluted and separated by
RP-HPLC on a SMART system equipped with a 
 
m
 
RPC C2/
C18 SC2.1/10 column (Amersham Pharmacia Biotech) using an
acetonitrile gradient in 0.1% TFA as described (23).The RP-HPLC
profiles obtained from independent separations were reproducible
and equivalent for the respective class II eluates of DO
 
2
 
 or DO
 
1
 
cells. 0.5 
 
m
 
l aliquots were sampled from each HPLC fraction and
analyzed by matrix-assisted laser-desorption time-of-flight mass
spectrometry using a TofSpec 2E mass spectrometer (Micromass)
fitted with a time-lag focusing source (33, 34).
 
Peptide Association Assay. 
 
HLA-DR3–CLIP complexes were
affinity purified from T2.DR3 cells using L243-coupled CNBr- 
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activated Sepharose as described previously (17). Mel JuSo cells
either transfected with DO
 
ab
 
GFP or with vector only were
lysed in 50 
 
m
 
M Tris-HCl, pH 8.0, containing 0.5% NP-40, 5 
 
m
 
M
EDTA, and protease inhibitors, followed by removal of nuclei
and debris by centrifugation. Protein concentrations of the differ-
ent lysates were determined by BCA (Pierce Chemical Co.) mea-
surements using BSA (Sigma Chemical Co.) as standard and ad-
justed to equal values. Exchange of CLIP from DR3–CLIP
complexes for biotinylated apolipoprotein B
 
 (
 
ApoB[2877–2894])
was determined by adding 2 
 
m
 
M of biotinylated peptide to 30
nM DR3–CLIP in buffer containing 50 
 
m
 
M Tris-HCl, 25 
 
m
 
M
Na
 
2
 
CO
 
3
 
, 2 
 
m
 
M EDTA, 0.1% NP-40, and 0.1 
 
m
 
M PMSF titrated
to the desired pH with 1 M citrate (35). Lysates from 
 
z
 
5 
 
3
 
 10
 
5
 
cells or lysis buffer only were added when appropriate. Western
blot analysis, using the DM
 
a
 
-specific mAb 5C1 (30) or the anti-
actin mAb Ab-1 (Oncogene) followed by quantification using
the FluorChem™ imaging system and AlphaEase™ FC software
(Alpha Innotech Corp.), confirmed that the lysates contained
identical amounts of DM and DM/DO. The time course of
ApoB(2877–2894) association at 37
 
8
 
C was followed until satura-
tion of peptide binding (24 h for pH 4.5–6.0 and 50 h for pH
7.0). MHC–peptide complexes were immunoprecipitated with
immobilized L243 antibody and peptides were detected via per-
oxidase-conjugated streptavidin (Amersham Pharmacia Bio-
tech). The absorbance at 405 nm was measured by an ELISA
reader (Multiskan Plus; Titertek) and nonspecific signals (quadru-
plicates, typically 15% of maximal absorbance) were subtracted
from the data (17, 35).
 
T Cell Proliferation Assay. 
 
Antigen presentation experiments
were performed essentially as described (23). In brief, Mel JuSo
cells were incubated for 4 h with 100 nM bafilomycin A
 
1
 
 (Bio-
mol) when appropriate, and subsequently pulsed with varying
amounts of sonicate of 
 
Mycobacterium tuberculosis
 
 either in the
presence or not of 40 nM bafilomycin A
 
1
 
. Subsequently, the cells
were irradiated at 8,000 rads and seeded in 96-well flat-bottomed
microtiter plates at cell concentrations triggering optimal T cell
proliferation (36), together with 10
 
4
 
 T cells from the HLA-DR3–
restricted, p3-13–specific T cell clone Rp15 1-1. As a control,
the HLA-DR3–restricted epitope, the p56-65 peptide of the 30–
31-kD protein of 
 
M
 
.
 
 tuberculosis
 
,
 
 
 
was added to nontreated, irradi-
ated cells. To check for toxicity due to the Bafilomycin A
 
1
 
 treat-
ment, T cell proliferation was measured in the presence of APCs
and 10% IL-2 (Lymphocult-T; Biotest). After 66 h in culture, 1
 
m
 
Ci [
 
3
 
H]thymidine was added, cells were collected 18 h later on
glass fiber filter strips, and the radioactivity incorporated in the
DNA was assessed by liquid scintillation counting (36).
 
Results and Discussion
 
DO Interferes with CLIP Release from Class II Molecules
and Reduces Antigenic Peptide Presentation. 
 
The function
of DO was studied using the human cell line Mel JuSo
(DO
 
2
 
, DM
 
1
 
, and HLA–DR3
 
1
 
; 23) and stable transfec-
tants expressing DO
 
ab
 
GFP with GFP (37) linked to the
cytoplasmic tail of DO
 
b
 
 without affecting DO function
(23). Although DO hampers the release of CLIP from
MHC class II molecules, it affects presentation of some
particular antigenic peptides, but not of others (22–24).
To get insight in the effect of DO on the overall effi-
ciency of antigenic peptide presentation by class II, FACS
 
®
 
analysis was performed on both DO
 
2
 
 and DO
 
1
 
 cells. The
 
amount of DO
 
ab
 
GFP in the DO
 
1
 
 cells was such that the
whole DM pool was quantitatively associated to DO (23).
DO
 
ab
 
GFP expression caused an 
 
z
 
50% reduction in
staining with the antibody 16.23 that recognizes HLA-
DR3–antigenic peptide complexes (28, 29), concomitant
with an increase in the relative amount of class II/CLIP
(Fig. 1 A). The total level of cell-surface expressed class II
remained unchanged (Fig. 1 A), nor did the level of DM
vary significantly (23). Thus, in cells with DM quantita-
tively associated to DO, the pool of class II presenting an-
tigenic peptides is reduced, but not eliminated. Since it
was recently suggested (38) that the inhibitory effect of
DO on CLIP release only occurred at high DO expression
levels, FACS
 
®
 
 analysis on a population of transfectants
Figure 1. DOabGFP affects peptide presentation by HLA-DR3. (A)
FACS® analysis of 5,000 Mel JuSo cells transfected either with DOab2
GFP (GFP1 population) or vector only (GFP2 population) showing
staining with secondary antibody only (2), or staining that is specific for
class II molecules (L243), CLIP-bound HLA-DR3 (CerCLIP.1), or
HLA-DR3 complexed to stably bound peptides (16.23). (B) FACS®
analysis of 5,000 Mel JuSo cells expressing various levels of DOabGFP,
showing specific staining of HLA-DR3–CLIP complexes by CerCLIP.1
antibody. The vertical axis represents GFP and the horizontal axis PE-
fluorescence derived from the secondary antibody, each in arbitrary units
on a logarithmic scale. Values next to the right axis indicate which DO-
abGFP populations were FACS® sorted for analysis of relative DO/DM
expression levels.1130 HLA-DO Modulates the MHC Class II–associated Peptide Repertoire
with various DOabGFP levels was performed. This dem-
onstrated an almost linear correlation between DOabGFP
expression and cell surface–expressed class II/CLIP, rang-
ing from a low, but detectable, amount of class II/CLIP in
DO2 cells to an almost two-log increase in cells with rela-
tively high DOabGFP levels (Fig. 1 B). Additional aug-
mentation of DOabGFP expression did not increase the
relative CLIP expression any further, suggesting that from
this point on DO expression was saturating for quantita-
tive association of DM to DO (Fig. 1 B). Identical results
were obtained when GFP and DOb were expressed as
separate proteins from one bicistronic transcript (data not
shown). FACS® sorting of different DOabGFP transfec-
tant populations (populations 2–5, Fig. 1 B) was per-
formed to quantify DM and DO expression (Table I).
Comparison of the relative DO/DM levels with that ob-
served in primary B cells showed that the relative DO/
DM level in primary B cells falls within the range of values
obtained from the transfectants studied (Table I). Thus,
DO invariably and quantitatively impedes CLIP removal
from newly synthesised class II molecules, also when ex-
pressed at levels that are comparable to the physiological B
cell levels.
DO Abolishes Presentation of a Set of Long Peptides Associ-
ated to Class II.  The effect of DO on the composition of
surface class II–peptide complexes was investigated more
closely using surface iodinated class II complexes from
DO1 and DO2 cells. Strikingly, MHC class II immuno-
precipitation using the HLA-DRa–specific mAb 1B5 led
to the coprecipitation of a set of iodinated peptides with
apparent molecular sizes ,18 kD in the DO2 cells, but not
in the DO1 cells (Fig. 2 A). These fragments were not re-
covered upon immunoprecipitation using mAbs specific
for the N or COOH terminus of the Ii, indicating that
they were not derived from the class II–associated Ii frag-
ments (Fig. 2 A). Moreover, when class II–Ii maturation
was compared between both DO1 and DO2 in pulse–
chase analysis, DO did not affect the intracellular transport
of class II (Fig. 2 B, top), nor the rate of breakdown of the
associated Ii. Ii breakdown intermediates (39) were recov-
ered at the same time points in both DO1 and DO2 cells,
apart from the expected recovery of CLIP at late time
points in DO1 cells only (Fig. 2 B, bottom). Notably, the
set of large peptides associated with class II at the cell sur-
face in DO2 cells did not correspond to the Ii fragments
observed in pulse–chase analysis (compare Fig. 2, A and B).
Together, these data show that DO generates both quanti-
tative differences in the pool of class II–associated peptides
Table I. Relative DO/DM Expression Levels in Mel
JuSO/DOabGFP Transfectants and Primary B Cells
Actin DMa DOb DOb/DMa
aU aU aU aU
Mel JuSo/DOabGFP
Population 2 1 1.2 0.04 0.03
Population 3 1 1.1 0.07 0.06
Population 4 1 1.1 0.9 0.82
Population 5 1 1 1 1
Primary B Cells 1 1.0–1.4* 0.45 0.3–0.5*
Quantification of DMa and DOb expression levels in transfectant Mel
JuSo cells sorted for different expression levels of DOabGFP and
primary B cells was performed using the FluorChem™ imaging system
and AlphaEase™ FC software. Relative DMa and DOb expression
levels (in arbitrary units, aU) are correlated to cellular actin levels (in
arbitrary units). 
*The expression levels of DMa (and consequently the DOb/DMa ra-
tio) in primary B cells is depicted as the range of values observed for
different primary B cell isolates.
Figure 2. DO alters the class II–associated peptides at
the cell surface. (A) SDS-PAGE of immunoprecipitated
material from surface iodinated Mel JuSo cells either
transfected (DO1) or not (DO2) with DOabGFP.
Proteins were precipitated using normal rabbit serum
(nrs), the anti–HLA-DRa mAb 1B5, or the anti-Ii
mAbs ICC5 (anti–COOH terminus) and ICN2 (anti–
NH2 terminus). The positions of the DR chains and Ii
are marked by arrows. The area containing iodinated
fragments associated with class II only in DO2 cells
(even upon prolonged exposure of the autoradiogram)
is indicated with an asterisk. Molecular marker sizes are
shown on the left (in kD). (B) Pulse–chase analysis of
[35S]Met-Cys–labeled MHC class II complexes of con-
trol Mel JuSo cells (DO2) or transfected with DOab2
GFP (DO1). Cells were labeled for 30 min and lysed
after chase in nonradioactive medium for the indicated
times, followed by isolation using the anti-DRa anti-
body 1B5. The top and bottom show a short and long
exposure, respectively, of the same autoradiogram. Mo-
lecular marker sizes are indicated on the left (in kD).1131 van Ham et al.
at the cell surface of APCs (as demonstrated by a 50% re-
duction of 16.23 staining; Fig. 1 A), as well as qualitative
differences in that class II–mediated presentation of long,
iodinable fragments is abrogated.
DO Generates Qualitative Differences in the Class II–associ-
ated Antigenic Peptide Repertoire.  To identify the nature
of the differences in the class II peptide repertoire gener-
ated by DO, HLA-DR3 molecules were purified from
both DO1 and DO2 cells. The associated peptides were
eluted, separated into .100 different fractions by RP-
HPLC and analyzed by matrix-assisted laser-desorption
time-of-flight mass spectrometry (33, 34). Analysis of the
fractions showed that the DO1 cells were highly enriched
in peptides with masses corresponding to various CLIP
variants in the late eluting fractions of the RP-HPLC, as
observed presiously (23). Both for DO2 and for DO1,
.500 individual mass species in antigenic peptide size (Mr
range of 13–21 amino acid residues) were identified in the
RP-HPLC fractions eluting before CLIP. Analysis of all of
these masses upon calibration showed that z90% of the
peptides were identical for both eluates (Fig. 3), with
masses being regarded as identical when (1) differing ,0.5
daltons and (2) eluting in equivalent fractions from the
RP-HPLC. Strikingly, z10% of the peptides were unique
either for the DO1 or DO2 cells (Fig. 3). These unique
peptides were found in several subsequent fractions of ei-
ther DO2 or DO1 eluate, but not in any of the fractions
of the other eluate. The average size of the unique pep-
Figure 3. DO modulates the antigenic
peptide repertoire of HLA-DR3. Mass
spectrometry profiles of four sets of equiva-
lent RP-HPLC fractions containing pep-
tides eluted from HLA-DR3 molecules
from DO2 and DO1 cells. Peptides that are
found in both depicted DO2 and DO1
fractions are denoted with a number. Non-
annotated peptide peaks are found in both
DO2 and DO1 eluates, but not in the cor-
responding fractions depicted. Peptides de-
noted with a specific mass are found in sev-
eral subsequent fractions of either DO2 or
DO1 eluate, but not in any of the fractions
of the other eluate.1132 HLA-DO Modulates the MHC Class II–associated Peptide Repertoire
tides did not vary significantly between both eluates. Thus,
apart from abrogating association of long peptide frag-
ments to class II, DO also alters the set of class II–associ-
ated antigenic peptides by suppressing presentation of cer-
tain peptides, while inducing presentation of others.
Therefore, DO has the unique property of modulating the
class II–mediated peptide repertoire, both by positive and
negative discrimination. This level of fastidiousness in se-
lecting peptides for loading onto presenting class II mole-
cules points to an unprecedented function for the DO
molecule in the immune system.
DO Modulates DM-mediated Class II–peptide Loading in a
pH-dependent Manner.  By which mechanism does DO
generate qualitative differences in the class II–associated
peptide repertoire? Different class II–peptide complexes
can be generated in distinct compartments of the endoso-
mal/lysosomal pathway in different pH environments (40–
45). The DM–DO complex constitutively recycles be-
tween the MIICs and the plasma membrane (data not
shown), implying that en route to the MIIC, both DM
and DO traverse all endocytic compartments where they
may support and modulate peptide loading. Recently, re-
combinant DO was reported to affect DM function in a
pH-sensitive manner in vitro (24). If true, this may illus-
trate how DO modulates the peptide repertoire. To deter-
mine if DO modulates DM activity in a pH-dependent
fashion in our transfectants, in vitro peptide loading exper-
iments were performed using DM and DM–DO com-
plexes obtained from either DO2 or DO1 cells in which
the whole DM pool was quantitatively associated to DO
(23, 30, 35). Equal amounts of DM and DM–DO were
applied in the experiments as quantified using the Fluor-
Chem™ imaging system and AlphaEase™ FC software
(data not shown). Exchange of CLIP from purified HLA-
DR3–CLIP for the antigenic peptide ApoB(2877–2894)
was indeed increasingly catalyzed by DM on acidification
with an optimum pH z5 (Fig. 4 A). DO-mediated inhibi-
tion of DM was strongest at the pH normally observed in
early lysosomes (pH z6), conditions in which the cata-
lytic capacity of DM is almost abrogated. DO still inhib-
ited DM at the pH described for the MIICs (pH 4.5–5),
but only by half (Fig. 4 A). Thus, these in vitro data sug-
gests that DO inhibits DM preferentially at the pH of
earlier endosomal compartments, while allowing substan-
tial DM-mediated peptide loading at the pH present in
MIICs.
The pH-sensing activity of DO was investigated under
more physiological conditions in antigen presentation as-
says (36) using bafilomycin A1, an inhibitor of vacuolar
ATPases (44). Confocal analyses showed that this strongly
reduced the acidification of the endosomal/lysosomal
compartments, with the majority of DM–DO still locating
to the MIICs (data not shown). Antigen presentation of
the p3-13 peptide of the hsp65 protein from M. tuberculosis
(36) was studied, as this peptide is loaded onto newly syn-
thesized class II molecules in acidic MIICs (its presentation
is abrogated upon brefeldin A incubation; data not
shown). Incubation of both DO2 and DO1 cells with
varying amounts of M. tuberculosis sonicate showed that
both transfectants presented the p3-13 peptide in a dose-
dependent manner (Fig. 4 B). DO expression reduced pre-
sentation (Fig. 4 B), in line with the in vitro peptide load-
ing abilities of DM–DO and DM at acidic pH (Fig. 4 A)
and our previous results (23). bafilomycin A1 strongly af-
fected p3-13 presentation upon incubation of DO2 cells
with M. tuberculosis sonicate, but still allowed presentation
at higher antigen concentrations (Fig. 4 B). However, ba-
filomycin A1 completely inhibited p3-13 peptide presenta-
tion in DO1 cells at all concentrations of M. tuberculosis
sonicate (Fig. 4 B). To exclude the possibility that bafilo-
mycin A1 inhibited antigen presentation in DO1 cells due
to the initial lower presentation capacities of nontreated
cells, antigen presentation was studied using a very high
amount of M. tuberculosis sonicate (100 mg/ml) with vary-
ing amounts of APC. In this way, the T cell proliferation
values induced by 1,500 and 3,000 nontreated DO1 cells
were higher than the proliferation values obtained with
6,000 nontreated DO2 cells (Fig. 4 C). Still, bafilomycin
A1 again completely abrogated p3-13 peptide presentation
at all DO1 concentrations, while only partially inhibiting
presentation by DO2 cells (even upon application of 6,000
DO2 cells/assay well; Fig. 4 C). Antigen presentation was
not affected by bafilomycin A1 when IL-2 was added to
the T cell–APC mixture, indicating that bafilomycin A1
was not toxic to the cells (Fig. 4 C). Thus, DO completely
inhibits DM-mediated class II–peptide loading in intracel-
lular compartments that are not effectively acidified. These
data demonstrate that DO indeed acts in a pH-dependent
fashion to regulate DM function. Translated to the physio-
logical situation, DO will inhibit DM-mediated peptide
loading in early endosomal compartments, while allowing
peptide binding to class II molecules in more acidic com-
partments, like the MIICs. In concordance with this are
descriptions of DM mediating class II–peptide binding in
MIICs, but not in early endosomes (42, 43, 45), consider-
ing that in those experiments DM was most likely com-
plexed to DO. The skewing by DO to DM-mediated
peptide loading in acidic compartments provides an expla-
nation for how DO inhibits class II–mediated presentation
of certain epitopes, especially large ones, while favoring
presentation of others.
DO May Serve to Control B Cell-driven Immune Responses.
DO is the first example of a physiological relevant pro-
tein that both limits and skews the class II–presented an-
tigenic peptide repertoire. Two distinct features of the
action of DO on class II–mediated antigen presentation are
apparent, one quantitative, the other qualitative. First, DO
downmodulates the levels of class II–antigen loading as a
whole by impeding CLIP release from class II, resulting in
a reduced, but not completely inhibited, presentation of
antigens and thus a diminished CD41 response. The ob-
served linearity between DO and DR–CLIP expression in-
dicates that even relatively low DO expression modulates
the class II response in this way. Second, DO results in the
presentation of certain peptides while suppressing others,
thus modulating the antigenic peptide repertoire. Presenta-1133 van Ham et al.
tion of long peptides is abrogated by DO, probably because
these fragments have already been trimmed down in the
later, acidic peptidase–containing (46) compartments where
DO allows peptide loading of class II. The finding that DO
is mainly expressed in B cells, and thus forms a cell type–
specific modulator, points to a B cell–specific need for
skewing peptide loading to acidic compartments. Since in a
B cell, specific antigens are taken up via the B cell receptor
and targeted to acidic MIICs (47, 48), DO may favor pre-
sentation of these antigens, while repressing presentation of
antigens continuously internalized via fluid phase endocy-
tosis. These modulatory actions of DO may increase the
threshold for nonspecific B cell activation, preventing non-
specific activation of the immune system and autoantibody
production.
We gratefully acknowledge G. Malcherek for the biotinylated
ApoB(2877–2894) peptide and P. Cresswell for the T2.DR3 cells
Figure 4. DO modulates DM function in a pH-dependent fashion. (A) In vitro association of biotinylated ApoB(2877–2894) to purified DR3–CLIP
complexes upon CLIP dissociation was measured at different pH values in the presence of cell lysates containing equal amounts of DM or DM–DOab2
GFP complexes (DM/DO) or lysis buffer only (2). Association is depicted as absorbance at 405 nm in arbitrary units (a.U.) upon saturation of the pep-
tide exchange reaction. The data shown were derived from a representative set of experiments (n 5 4). (B) Antigen-presenting capacity of p3-13–reactive
T cell clone Rp15 1-1 using control (DM) and DOabGFP-expressing cells (DM/DO) at prevention of acidification of the endosomal/lysosomal path-
way. T cell proliferation is expressed as the amount of [3H]thymidine incorporation in cpm and was determined for varying amounts of M. tuberculosis
sonicate with 1,500 APCs/assay well. Data shown were derived from a representative experiment performed three times; SEM ,10%. T cell prolifera-
tion in response to Mel JuSo cells pulsed with HLA-DR3–restricted peptide p56-65 was not significant, and application of Mel JuSo transfected with DO
without GFP tag resulted in the same effects as the DOabGFP transfectants (data not shown). (C) Antigen-presenting capacity of p3-13–reactive T cell
clone Rp15 1-1 using varying amounts of control (DM) and DOabGFP-expressing cells (DM/DO) at prevention of acidification of the endosomal/
lysosomal pathway. T cell proliferation (measured by [3H]thymidine incorporation) was determined using 100 mg/ml M. tuberculosis sonicate. Data shown
were derived from a representative experiment performed three times; SEM ,10%. Application of Mel JuSo transfected with DO without GFP tag
yielded the same results as the DOabGFP transfectants (data not shown). Black bars, DM 1 M. tuberculosis; gray bars, DM 1 medium; lined bars, DM-
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